News

A tiered level preceptor recognition program offers a cost-effective organizational intervention designed to acknowledge and incentivize the contributions of advanced practice preceptors.

The FDA granted tamibarotene plus azacitidine and venetoclax fast track designation for the treatment of newly diagnosed, unfit, RARA-overexpressed AML.

Superior 3-year survival outcomes were observed with durvalumab plus chemotherapy compared with chemotherapy alone in patients with advanced biliary tract cancer.

Breast-conserving therapy following preoperative systemic therapy resulted in superior overall survival compared with mastectomy in patients with HER2-positive breast cancer.

Oncology nurses play a vital role in informing patients about the importance of molecular testing and brain imaging in EGFR-mutated lung cancer.

The FDA’s Oncologic Drugs Advisory Committee voted in favor of minimal residual disease as an end point to support accelerated approval of multiple myeloma treatments.

Patients with renal cell carcinoma who did not undergo surgical resection and were treated with stereotactic ablative body radiotherapy experienced high local control rates with an acceptable side effect profile.

Patients with metastatic microsatellite stable colorectal cancer treated with a personalized neoantigen cancer vaccine after chemotherapy demonstrated an early trend towards a progression-free survival benefit.

Advanced care planning can benefit both the patients with cancer and the oncology nurses who work in intensive care units, as it may potentially reduce stress and moral distress.

One expert explains the importance of deciphering the data obtained through wearable technology while aiming to avoid data fatigue in oncology nurses.

Patients with gastric/GEJ adenocarcinoma treated with cadonilimab plus oxaliplatin and capecitabine obtained a survival benefit regardless of PD-L1 expression.

The journey toward vicarious resilience is not only possible but essential—for ourselves, our patients, and it is the very essence of health care.

Genetic testing decisions in patients with cancer may be affected by significant out-of-pocket costs.

Oncology nurses provide patients with lung cancer the education and empathy needed to navigate treatment options and adverse event management.

Compared with docetaxel, adagrasib improved progression-free survival and objective response rate in patients with pretreated KRAS G12C–mutant non–small cell lung cancer.

Significant advances have been made in diagnosing and treating bladder cancer, allowing for improved patient outcomes.

Tumor-treating fields significantly improved the time to intracranial progression in patients from the phase 3 METIS trial with brain metastases from non-small cell lung cancer.

Cilta-cel (ciltacabtagene autoleucel; Carvykti) was approved by the FDA to treat patients with relapsed or refractory multiple myeloma who have previously received at least one line of therapy.

The FDA granted LSTA1 rare pediatric disease designation for the treatment of osteosarcoma.

As part of a survey of practicing oncologists in the United States, clinicians may have ethical concerns around using artificial intelligence in cancer care.

The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive solid tumors who have received prior systemic treatment.

In the April 2024 issue of Oncology Nursing News, stories focus on bladder-preserving treatment options in bladder cancer, recent FDA approvals, conference news, and embracing vicarious resilience.

The FDA has approved idecabtagene vicleucel for patients with relapsed/refractory multiple myeloma who have received 2 prior lines of therapy.

First-line treatment with osimertinib and chemotherapy significantly improved survival outcomes after disease progression in EGFR-mutated NSCLC.

Research is focusing more on the realities of a cystectomy and how to improve treatment options.

Findings from this study demonstrated effectiveness with frontline ibrutinib in patients with previously treated, low-risk mantle cell lymphoma regardless of whether rituximab was added.

The biologics license application for datopotamab deruxtecan has been accepted by the FDA for pretreated HR-positive, HER2-negative metastatic breast cancer.

First-line treatment with anlotinib plus chemotherapy improved progression-free survival compared with chemotherapy plus placebo in patients with extensive-stage small cell lung cancer.